Nuvectis Pharma, Inc. (NVCT)
Market Cap | 127.39M |
Revenue (ttm) | n/a |
Net Income (ttm) | -22.38M |
Shares Out | 18.36M |
EPS (ttm) | -1.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,097 |
Open | 6.74 |
Previous Close | 6.62 |
Day's Range | 6.53 - 6.95 |
52-Week Range | 5.85 - 15.50 |
Beta | 0.45 |
Analysts | Strong Buy |
Price Target | 21.00 (+202.59%) |
Earnings Date | Aug 7, 2024 |
About NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NVCT stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
![](https://cdn.snapi.dev/images/v1/z/r/conf16-2434637.jpg)
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p...
![](https://cdn.snapi.dev/images/v1/l/t/press10-2414460.jpg)
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/3/a/press6-2360867.jpg)
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to...
![](https://cdn.snapi.dev/images/v1/o/i/press13-2330710.jpg)
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/j/h/conf7-2326297.jpg)
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatme...
![](https://cdn.snapi.dev/images/v1/q/3/press15-2324302.jpg)
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serio...
![](https://cdn.snapi.dev/images/v1/a/0/press14-2308266.jpg)
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
FORT LEE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati...
![](https://cdn.snapi.dev/images/v1/e/q/conf5-2269216.jpg)
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...
![](https://cdn.snapi.dev/images/v1/f/t/conf19-2269142.jpg)
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...
![](https://cdn.snapi.dev/images/v1/4/c/conf11-2214513.jpg)
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...
![](https://cdn.snapi.dev/images/v1/n/7/press12-2146647.jpg)
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
![](https://cdn.snapi.dev/images/v1/m/n/conf18-2077191.jpg)
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/p/e/press17-2072497.jpg)
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/2/l/press16-2051114.jpg)
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
![](https://cdn.snapi.dev/images/v1/i/f/press1-2026843.jpg)
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...
![](https://cdn.snapi.dev/images/v1/8/i/press15-2014494.jpg)
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
![](https://cdn.snapi.dev/images/v1/b/c/press11-1889743.jpg)
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p...
![](https://cdn.snapi.dev/images/v1/j/4/press10-1882010.jpg)
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
FORT LEE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/k/p/conf3-1858145.jpg)
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is Ma...
![](https://cdn.snapi.dev/images/v1/i/p/press1-1830515.jpg)
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Phase 1b study builds on highly consistent preclinical and Phase 1a data Phase 1b study builds on highly consistent preclinical and Phase 1a data
![](https://cdn.snapi.dev/images/v1/l/a/press20-1801768.jpg)
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
![](https://cdn.snapi.dev/images/v1/a/m/press4-1791209.jpg)
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatme...
![](https://cdn.snapi.dev/images/v1/y/j/press7-1785304.jpg)
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati...
![](https://cdn.snapi.dev/images/v1/p/o/press1-1658379.jpg)
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medici...
![](https://cdn.snapi.dev/images/v1/y/t/press11-1624629.jpg)
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medi...